Sands Capital Management, LLC Bluebird Bio, Inc. Transaction History

Sands Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 12, 2021	SELL	$16.59 - $33.89 $52.5 Million - $107 Million	-3,163,651 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $881,760 - $1.22 Million	-32,064 Reduced 1.0%	3,163,651 $137 Million
Q3 2020 Nov 16, 2020	BUY	$34.44 - $43.75 $2.24 Million - $2.85 Million	65,164 Added 2.08%	3,195,715 $172 Million
Q2 2020 Aug 11, 2020	BUY	$27.12 - $45.97 $283,539 - $480,616	10,455 Added 0.34%	3,130,551 $191 Million
Q1 2020 May 14, 2020	SELL	$26.16 - $63.5 $1.48 Million - $3.59 Million	-56,548 Reduced 1.78%	3,120,096 $143 Million
Q4 2019 Feb 13, 2020	BUY	$46.96 - $61.67 $46.8 Million - $61.5 Million	996,481 Added 45.71%	3,176,644 $279 Million
Q3 2019 Nov 14, 2019	BUY	$59.47 - $93.1 $63.7 Million - $99.8 Million	1,071,629 Added 96.67%	2,180,163 $200 Million
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $84.1 Million - $117 Million	1,108,534 New	1,108,534 $141 Million

152

63.7M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $24.7M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Sands Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sands Capital Management, LLC with notifications on news.